<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">diaendo</journal-id><journal-title-group><journal-title xml:lang="ru">Сахарный диабет</journal-title><trans-title-group xml:lang="en"><trans-title>Diabetes mellitus</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0351</issn><issn pub-type="epub">2072-0378</issn><publisher><publisher-name>Endocrinology research centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/DM12756</article-id><article-id custom-type="elpub" pub-id-type="custom">diaendo-12756</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Влияние пероральных сахароснижающих препаратов на пуриновый обмен</article-title><trans-title-group xml:lang="en"><trans-title>Effect of oral antihyperglycemic drugs on purine metabolism</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5290-156X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Паневин</surname><given-names>Т. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Panevin</surname><given-names>T. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Паневин Тарас Сергеевич, к.м.н. </p><p>115522, Москва, Каширское шоссе, д. 34А </p><p>eLibrary SPIN-код: 7839-3145 </p></bio><bio xml:lang="en"><p>Taras S. Panevin, MD, PhD</p><p>34A Kashirskoe Shosse, 115522 Moscow</p><p>eLibrary SPIN-код: 7839-3145 </p></bio><email xlink:type="simple">tarasel@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт ревматологии им. В.А. Насоновой; Консультативно-диагностический центр Генерального штаба Вооруженных сил Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology; Advisory and Diagnostic center of the General Staff of the Armed Forces of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>10</day><month>08</month><year>2021</year></pub-date><volume>24</volume><issue>4</issue><fpage>342</fpage><lpage>349</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Паневин Т.С., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Паневин Т.С.</copyright-holder><copyright-holder xml:lang="en">Panevin T.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.dia-endojournals.ru/jour/article/view/12756">https://www.dia-endojournals.ru/jour/article/view/12756</self-uri><abstract><p>Подагра и сахарный диабет — обменные заболевания, в основе патогенеза которых лежит избыток в организме органических молекул, в первом случае — мочевой кислоты (МК), во втором — глюкозы. Предполагается, что МК может принимать участие и в патогенезе сахарного диабета 2 типа (СД2), а инсулинорезистентность и гипергликемия — влиять на пуриновый обмен. Оба заболевания ассоциированы с повышенным риском развития кардиоваскулярных событий. Кроме того, хроническое микрокристаллическое воспаление, которое отсутствует при бессимптомной гиперурикемии, но является обязательным компонентом подагры, вероятно, является независимым фактором СД2, артериальной гипертензии и кардиоваскулярных событий. Лечение обоих заболеваний стратегически схоже: при подагре целью является достижение нормального уровня МК крови, при СД2 — нормализация гликемии, а частое сочетание указанных обменных заболеваний требует учитывать влияние лекарственной терапии на сопутствующие заболевания. Большинство современных сахароснижающих препаратов может оказывать влияние на пуриновый обмен, что подтверждается результатами ряда зарубежных работ. В то же время влияние терапии СД2 на пуриновый обмен и подагру недостаточно освещено в отечественной литературе, что и стало целью настоящего обзора.</p></abstract><trans-abstract xml:lang="en"><p>Gout and diabetes mellitus are metabolic diseases, the pathogenesis of which is based on an excess of organic molecules in the body, in the first case — uric acid (UA), in the second — glucose. It is assumed that UA can also be involved in the pathogenesis of type 2 diabetes mellitus (T2DM), while insulin resistance and hyperglycemia affect purine metabolism. Both diseases are associated with an increased risk of cardiovascular events. In addition, chronic microcrystalline inflammation, which is absent in asymptomatic hyperuricemia, but is an obligatory component of gout, is probably an independent factor in T2DM, arterial hypertension, and cardiovascular events. The treatment of both diseases is strategically similar: in gout, the goal is to achieve a normal blood MC level, in T2DM — to normalize glycemia, and the frequent combination of these metabolic diseases requires taking into account the effect of drug therapy on concomitant diseases. Most modern antihyperglycemic drugs can affect purine metabolism, which is confirmed by the results of a number of foreign works. At the same time, the effect of T2DM therapy on purine metabolism and gout has not been adequately covered in the domestic literature, which was the purpose of this review.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>сахарный диабет 2 типа</kwd><kwd>подагра</kwd><kwd>гиперурикемия</kwd><kwd>мочевая кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>type 2 diabetes mellitus</kwd><kwd>gout</kwd><kwd>hyperuricemia</kwd><kwd>uric acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Yamamoto T, Hisatome I, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 2013;375(1-2):89-96. doi: https://doi.org/10.1016/j.mce.2013.04.027</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Yamamoto T, Hisatome I, et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 2013;375(1-2):89-96. doi: https://doi.org/10.1016/j.mce.2013.04.027</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009;30(1):96-116. doi: https://doi.org/10.1210/er.2008-0033</mixed-citation><mixed-citation xml:lang="en">Johnson RJ, Perez-Pozo SE, Sautin YY, et al. Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? Endocr Rev. 2009;30(1):96-116. doi: https://doi.org/10.1210/er.2008-0033</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008-3011. doi: https://doi.org/10.1001/jama.1991.03470210076036</mixed-citation><mixed-citation xml:lang="en">Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266(21):3008-3011. doi: https://doi.org/10.1001/jama.1991.03470210076036</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31(2):361-362. doi: https://doi.org/10.2337/dc07-1276</mixed-citation><mixed-citation xml:lang="en">Dehghan A, van Hoek M, Sijbrands EJ, et al. High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008;31(2):361-362. doi: https://doi.org/10.2337/dc07-1276</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737-1742. doi: https://doi.org/10.2337/dc09-0288</mixed-citation><mixed-citation xml:lang="en">Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009;32(9):1737-1742. doi: https://doi.org/10.2337/dc09-0288</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc. Disord. 2016;16(1):207. doi: https://doi.org/10.1186/s12872-016-0379-z71</mixed-citation><mixed-citation xml:lang="en">Zuo T, Liu X, Jiang L, et al. Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc. Disord. 2016;16(1):207. doi: https://doi.org/10.1186/s12872-016-0379-z71</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Кобалава Ж.Д., Киякбаев Г.К. Влияние сахароснижающих препаратов на риск сердечно-сосудистых осложнений при сахарном диабете 2-го типа: реалии и перспективы // Кардиология. — 2018. — Т. 58. — №1. — С. 53-65. [Kobalava ZD, Kiyakbaev GK. Effects of Glucose Lowering Drugs on Cardiovascular Risk in Type 2 Diabetes Mellitus: Realities and Perspectives. Kardiologiia. 2018;58(1):53-65. (In Russ.)]. doi: https://doi.org/10.18087/cardio.2018.1.10082</mixed-citation><mixed-citation xml:lang="en">Кобалава Ж.Д., Киякбаев Г.К. Влияние сахароснижающих препаратов на риск сердечно-сосудистых осложнений при сахарном диабете 2-го типа: реалии и перспективы // Кардиология. — 2018. — Т. 58. — №1. — С. 53-65. [Kobalava ZD, Kiyakbaev GK. Effects of Glucose Lowering Drugs on Cardiovascular Risk in Type 2 Diabetes Mellitus: Realities and Perspectives. Kardiologiia. 2018;58(1):53-65. (In Russ.)]. doi: https://doi.org/10.18087/cardio.2018.1.10082</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis &amp; Rheumatism. 2011;63(10):3136-3141. doi: https://doi.org/10.1002/art.30520</mixed-citation><mixed-citation xml:lang="en">Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. Arthritis &amp; Rheumatism. 2011;63(10):3136-3141. doi: https://doi.org/10.1002/art.30520</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Sánchez-Lozada LG, Tapia E, Bautista-García P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294(4):F710-F718. doi: https://doi.org/10.1152/ajprenal.00454.2007</mixed-citation><mixed-citation xml:lang="en">Sánchez-Lozada LG, Tapia E, Bautista-García P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2008;294(4):F710-F718. doi: https://doi.org/10.1152/ajprenal.00454.2007</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Therapy. 2014;5(2):355-366. doi: https://doi.org/10.1007/s13300-014-0089-4</mixed-citation><mixed-citation xml:lang="en">Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Therapy. 2014;5(2):355-366. doi: https://doi.org/10.1007/s13300-014-0089-4</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao Y, Xu L, Tian D, et al. Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2017;20(2):458-462. doi: https://doi.org/10.1111/dom.13101</mixed-citation><mixed-citation xml:lang="en">Zhao Y, Xu L, Tian D, et al. Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. 2017;20(2):458-462. doi: https://doi.org/10.1111/dom.13101</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Xin Y, Guo Y, Li Y, et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi Journal of Biological Sciences. 2019;26(2):421-426. doi: https://doi.org/10.1016/j.sjbs.2018.11.013</mixed-citation><mixed-citation xml:lang="en">Xin Y, Guo Y, Li Y, et al. Effects of sodium glucose cotransporter-2 inhibitors on serum uric acid in type 2 diabetes mellitus: A systematic review with an indirect comparison meta-analysis. Saudi Journal of Biological Sciences. 2019;26(2):421-426. doi: https://doi.org/10.1016/j.sjbs.2018.11.013</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Li J, Badve SV, Zhou Z, et al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. The Lancet Rheumatology. 2019;1(4):e220-e228. doi: https://doi.org/10.1016/s2665-9913(19)30078-5</mixed-citation><mixed-citation xml:lang="en">Li J, Badve SV, Zhou Z, et al. The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. The Lancet Rheumatology. 2019;1(4):e220-e228. doi: https://doi.org/10.1016/s2665-9913(19)30078-5</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой // Терапевтический архив. — 2020. — Т. 92. — №5. — С. 110-118. [Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Therapeutic Archive. 2020;92(5):110-118. (In Russ.)]. doi: https://doi.org/10.26442/00403660.2020.05.000633</mixed-citation><mixed-citation xml:lang="en">Паневин Т.С., Елисеев М.С., Шестакова М.В., Насонов Е.Л. Преимущества терапии ингибиторами натрий-глюкозного котранспортера 2 типа у пациентов с сахарным диабетом 2 типа в сочетании с гиперурикемией и подагрой // Терапевтический архив. — 2020. — Т. 92. — №5. — С. 110-118. [Panevin TS, Eliseev MS, Shestakova MV, Nasonov EL. Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Therapeutic Archive. 2020;92(5):110-118. (In Russ.)]. doi: https://doi.org/10.26442/00403660.2020.05.000633</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. Remuzzi G, editor. PLOS ONE. 2016;11(7):e0158765. doi: https://doi.org/10.1371/journal.pone.0158765</mixed-citation><mixed-citation xml:lang="en">Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. Remuzzi G, editor. PLOS ONE. 2016;11(7):e0158765. doi: https://doi.org/10.1371/journal.pone.0158765</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. American Journal of Physiology-Renal Physiology. 2014;306(2):F194-F204. doi: https://doi.org/10.1152/ajprenal.00520.2013</mixed-citation><mixed-citation xml:lang="en">Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. American Journal of Physiology-Renal Physiology. 2014;306(2):F194-F204. doi: https://doi.org/10.1152/ajprenal.00520.2013</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Liao X, Wang X, Li H, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes. Scientific Reports. 2016;6(1):32887. doi: https://doi.org/10.1038/srep32887</mixed-citation><mixed-citation xml:lang="en">Liao X, Wang X, Li H, et al. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes. Scientific Reports. 2016;6(1):32887. doi: https://doi.org/10.1038/srep32887</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Scientific Reports. 2018;8(1):5276. doi: https://doi.org/10.1038/s41598-018-23420-4</mixed-citation><mixed-citation xml:lang="en">Mancini SJ, Boyd D, Katwan OJ, et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Scientific Reports. 2018;8(1):5276. doi: https://doi.org/10.1038/s41598-018-23420-4</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Coperchini F, Leporati P, Rotondi M, Chiovato L. Expanding the therapeutic spectrum of metformin: from diabetes to cancer. Journal of Endocrinological Investigation. 2015;38(10):1047-1055. doi: https://doi.org/10.1007/s40618-015-0370-z</mixed-citation><mixed-citation xml:lang="en">Coperchini F, Leporati P, Rotondi M, Chiovato L. Expanding the therapeutic spectrum of metformin: from diabetes to cancer. Journal of Endocrinological Investigation. 2015;38(10):1047-1055. doi: https://doi.org/10.1007/s40618-015-0370-z</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lin HY-H, Chang K-T, Hung C-C, et al. Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines. BMC Immunol. 2014;15(1):37. doi: https://doi.org/10.1186/s12865-014-0037-0</mixed-citation><mixed-citation xml:lang="en">Lin HY-H, Chang K-T, Hung C-C, et al. Effects of the mTOR inhibitor Rapamycin on Monocyte-Secreted Chemokines. BMC Immunol. 2014;15(1):37. doi: https://doi.org/10.1186/s12865-014-0037-0</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">O’Neill LAJ, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013;493(7432):346-355. doi: https://doi.org/10.1038/nature11862</mixed-citation><mixed-citation xml:lang="en">O’Neill LAJ, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature. 2013;493(7432):346-355. doi: https://doi.org/10.1038/nature11862</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Bułdak Ł, Machnik G, Bułdak RJ, et al. Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2016;389(10):1103-1115. doi: https://doi.org/10.1007/s00210-016-1277-8</mixed-citation><mixed-citation xml:lang="en">Bułdak Ł, Machnik G, Bułdak RJ, et al. Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2016;389(10):1103-1115. doi: https://doi.org/10.1007/s00210-016-1277-8</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Menegazzo L, Scattolini V, Cappellari R, et al. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetologica. 2018;55(6):593-601. doi: https://doi.org/10.1007/s00592-018-1129-8</mixed-citation><mixed-citation xml:lang="en">Menegazzo L, Scattolini V, Cappellari R, et al. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetologica. 2018;55(6):593-601. doi: https://doi.org/10.1007/s00592-018-1129-8</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Vazirpanah N, Ottria A, van der Linden M, et al. mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy? Annals of the Rheumatic Diseases. 2019;78(5):663-671. doi: https://doi.org/10.1136/annrheumdis-2018-214656</mixed-citation><mixed-citation xml:lang="en">Vazirpanah N, Ottria A, van der Linden M, et al. mTOR inhibition by metformin impacts monosodium urate crystal–induced inflammation and cell death in gout: a prelude to a new add-on therapy? Annals of the Rheumatic Diseases. 2019;78(5):663-671. doi: https://doi.org/10.1136/annrheumdis-2018-214656</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Bruderer SG, Bodmer M, Jick SS, Meier CR. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study. Annals of the Rheumatic Diseases. 2014;74(9):1651-1658. doi: https://doi.org/10.1136/annrheumdis-2014-205337</mixed-citation><mixed-citation xml:lang="en">Bruderer SG, Bodmer M, Jick SS, Meier CR. Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study. Annals of the Rheumatic Diseases. 2014;74(9):1651-1658. doi: https://doi.org/10.1136/annrheumdis-2014-205337</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Шестаков А.В., Саприна Т.В., Ануфрак И.А., и др. Метформин: новые перспективы в химиопрофилактике и терапии рака // Российский биотерапевтический журнал. — 2018. — Т. 17. — №3. — С. 12-19. [Shestakov AV, Saprina TV, Anufrak IA, et al. Metformin: new perspectives in chemoprevention and therapy of cancer. Russian Journal of Biotherapy. 2018;17(3):12-19 (In Russ.)]. doi: https://doi.org/10.17650/1726-9784-2018-17-3-12-19</mixed-citation><mixed-citation xml:lang="en">Шестаков А.В., Саприна Т.В., Ануфрак И.А., и др. Метформин: новые перспективы в химиопрофилактике и терапии рака // Российский биотерапевтический журнал. — 2018. — Т. 17. — №3. — С. 12-19. [Shestakov AV, Saprina TV, Anufrak IA, et al. Metformin: new perspectives in chemoprevention and therapy of cancer. Russian Journal of Biotherapy. 2018;17(3):12-19 (In Russ.)]. doi: https://doi.org/10.17650/1726-9784-2018-17-3-12-19</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Барскова В.Г., Елисеев М.С., Кудаева Ф.М., и др. Влияние метформина на течение подагры и инсулинорезистентность // Клиническая медицина. — 2009. — Т. 87. — №7. — С. 41-46. [Barskova VG, Eliseev MS, Kudaeva FM, et al. Effect of metformine on the clinical course of gout and insulin resistance. Clinical medicine. 2009;87(7):41-46 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Барскова В.Г., Елисеев М.С., Кудаева Ф.М., и др. Влияние метформина на течение подагры и инсулинорезистентность // Клиническая медицина. — 2009. — Т. 87. — №7. — С. 41-46. [Barskova VG, Eliseev MS, Kudaeva FM, et al. Effect of metformine on the clinical course of gout and insulin resistance. Clinical medicine. 2009;87(7):41-46 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: https://doi.org/10.1038/nature04516</mixed-citation><mixed-citation xml:lang="en">Martinon F, Pétrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241. doi: https://doi.org/10.1038/nature04516</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Jacques C, Gosset M, Berenbaum F, Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm. 2006;74:371-403. doi: https://doi.org/10.1016/S0083-6729(06)74016-X</mixed-citation><mixed-citation xml:lang="en">Jacques C, Gosset M, Berenbaum F, Gabay C. The role of IL-1 and IL-1Ra in joint inflammation and cartilage degradation. Vitam Horm. 2006;74:371-403. doi: https://doi.org/10.1016/S0083-6729(06)74016-X</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Collins KH, Paul HA, Reimer RA, et al. Relationship between inflammation, the gut microbiota, and metabolic osteoarthritis development: studies in a rat model. Osteoarthritis Cartilage. 2015;23(11):1989-1998. doi: https://doi.org/10.1016/j.joca.2015.03.014</mixed-citation><mixed-citation xml:lang="en">Collins KH, Paul HA, Reimer RA, et al. Relationship between inflammation, the gut microbiota, and metabolic osteoarthritis development: studies in a rat model. Osteoarthritis Cartilage. 2015;23(11):1989-1998. doi: https://doi.org/10.1016/j.joca.2015.03.014</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">De la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut. Diabetes Care. 2016;40(1):54-62. doi: https://doi.org/10.2337/dc16-1324</mixed-citation><mixed-citation xml:lang="en">De la Cuesta-Zuluaga J, Mueller NT, Corrales-Agudelo V, et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut. Diabetes Care. 2016;40(1):54-62. doi: https://doi.org/10.2337/dc16-1324</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Coletta DK, Sriwijitkamol A, Wajcberg E, et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia. 2009;52(4):723-732. doi: https://doi.org/10.1007/s00125-008-1256-9</mixed-citation><mixed-citation xml:lang="en">Coletta DK, Sriwijitkamol A, Wajcberg E, et al. Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial. Diabetologia. 2009;52(4):723-732. doi: https://doi.org/10.1007/s00125-008-1256-9</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med. 2008;14(12):539-549. doi: https://doi.org/10.1016/j.molmed.2008.09.007</mixed-citation><mixed-citation xml:lang="en">Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med. 2008;14(12):539-549. doi: https://doi.org/10.1016/j.molmed.2008.09.007</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Iwatani M, Wasada T, Katsumori K. Troglitazone decreases serum uric acid concentrations in Type II diabetic patients and non-diabetics. Diabetologia. 2000;43(6):814-815. doi: https://doi.org/10.1007/s001250051380</mixed-citation><mixed-citation xml:lang="en">Iwatani M, Wasada T, Katsumori K. Troglitazone decreases serum uric acid concentrations in Type II diabetic patients and non-diabetics. Diabetologia. 2000;43(6):814-815. doi: https://doi.org/10.1007/s001250051380</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J. 1986;62(733):1001-1006. doi: https://doi.org/10.1136/pgmj.62.733.1001</mixed-citation><mixed-citation xml:lang="en">Cook DG, Shaper AG, Thelle DS, Whitehead TP. Serum uric acid, serum glucose and diabetes: relationships in a population study. Postgrad Med J. 1986;62(733):1001-1006. doi: https://doi.org/10.1136/pgmj.62.733.1001</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">González-Ortiz M, Hernández-Salazar E, Kam-Ramos AM, Martínez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;75(1):115-118. doi: https://doi.org/10.1016/j.diabres.2006.05.003</mixed-citation><mixed-citation xml:lang="en">González-Ortiz M, Hernández-Salazar E, Kam-Ramos AM, Martínez-Abundis E. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;75(1):115-118. doi: https://doi.org/10.1016/j.diabres.2006.05.003</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Gerber P, Lübben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2003;19(6):532-539. doi: https://doi.org/10.1185/030079903125002180</mixed-citation><mixed-citation xml:lang="en">Gerber P, Lübben G, Heusler S, Dodo A. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2003;19(6):532-539. doi: https://doi.org/10.1185/030079903125002180</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24(10):2047-2055. doi: https://doi.org/10.1097/01.hjh.0000244955.39491.88</mixed-citation><mixed-citation xml:lang="en">Bakris GL, Ruilope LM, McMorn SO, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens. 2006;24(10):2047-2055. doi: https://doi.org/10.1097/01.hjh.0000244955.39491.88</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clinical Pract. 2006;71(1):52-58. doi: https://doi.org/10.1016/j.diabres.2005.05.009</mixed-citation><mixed-citation xml:lang="en">Seber S, Ucak S, Basat O, Altuntas Y. The effect of dual PPAR α/γ stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients. Diabetes Res Clinical Pract. 2006;71(1):52-58. doi: https://doi.org/10.1016/j.diabres.2005.05.009</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Maalouf NM, Poindexter JR, Adams-Huet B, et al. The increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone. Kidney Int. 2019;95(5):1262-1268. doi: https://doi.org/10.1016/j.kint.2018.11.024</mixed-citation><mixed-citation xml:lang="en">Maalouf NM, Poindexter JR, Adams-Huet B, et al. The increased production and reduced urinary buffering of acid in uric acid stone formers is ameliorated by pioglitazone. Kidney Int. 2019;95(5):1262-1268. doi: https://doi.org/10.1016/j.kint.2018.11.024</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Maalouf NM, Sakhaee K, Parks JH, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422-1425. doi: https://doi.org/10.1111/j.1523-1755.2004.00522.x</mixed-citation><mixed-citation xml:lang="en">Maalouf NM, Sakhaee K, Parks JH, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004;65(4):1422-1425. doi: https://doi.org/10.1111/j.1523-1755.2004.00522.x</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Haffner SM, Greenberg AS, Weston WM, et al. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation. 2002;106(6):679-684. doi: https://doi.org/10.1161/01.cir.0000025403.20953.23</mixed-citation><mixed-citation xml:lang="en">Haffner SM, Greenberg AS, Weston WM, et al. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus. Circulation. 2002;106(6):679-684. doi: https://doi.org/10.1161/01.cir.0000025403.20953.23</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Wang RC, Jiang DM. PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet Mol Res. 2014;13(3):6577-6581. doi: https://doi.org/10.4238/2014.august.28.2</mixed-citation><mixed-citation xml:lang="en">Wang RC, Jiang DM. PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines. Genet Mol Res. 2014;13(3):6577-6581. doi: https://doi.org/10.4238/2014.august.28.2</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Niu SW, Chang KT, Lin HY, et al. Decreased incidence of gout in diabetic patient s using pioglitazone. Rheumatology (Oxford). 2017;57(1):92-99. doi: https://doi.org/10.1093/rheumatology/kex363</mixed-citation><mixed-citation xml:lang="en">Niu SW, Chang KT, Lin HY, et al. Decreased incidence of gout in diabetic patient s using pioglitazone. Rheumatology (Oxford). 2017;57(1):92-99. doi: https://doi.org/10.1093/rheumatology/kex363</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol. 2017;48(1):52-108. doi: https://doi.org/10.1080/10408444.2017.1351420</mixed-citation><mixed-citation xml:lang="en">Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol. 2017;48(1):52-108. doi: https://doi.org/10.1080/10408444.2017.1351420</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Паневин Т.С., Желябина О.В., Елисеев М.С., Шестакова М.В. Уратснижающие эффекты ингибиторов дипептидилпептидазы-4 // Сахарный диабет. — 2020. — Т. 23. — №4. — С. 349-356 [Panevin TS, Zhelyabina OV, Eliseev MS, Shestakova MV. Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Diabetes Mellitus. 2020;23(4):349-356. (In Russ.)]. doi: https://doi.org/10.14341/DM12412</mixed-citation><mixed-citation xml:lang="en">Паневин Т.С., Желябина О.В., Елисеев М.С., Шестакова М.В. Уратснижающие эффекты ингибиторов дипептидилпептидазы-4 // Сахарный диабет. — 2020. — Т. 23. — №4. — С. 349-356 [Panevin TS, Zhelyabina OV, Eliseev MS, Shestakova MV. Urate-lowering effects of dipeptidyl peptidase-4 inhibitors. Diabetes Mellitus. 2020;23(4):349-356. (In Russ.)]. doi: https://doi.org/10.14341/DM12412</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Rufinatscha K, Radlinger B, Dobner J, et al. Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes. Biochemical and Biophysical Research Communications. 2017;485(2):366-371. doi: https://doi.org/10.1016/j.bbrc.2017.02.071</mixed-citation><mixed-citation xml:lang="en">Rufinatscha K, Radlinger B, Dobner J, et al. Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes. Biochemical and Biophysical Research Communications. 2017;485(2):366-371. doi: https://doi.org/10.1016/j.bbrc.2017.02.071</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Itou M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol. 2013;19(15):2298. doi: https://doi.org/10.3748/wjg.v19.i15.2298</mixed-citation><mixed-citation xml:lang="en">Itou M. Dipeptidyl peptidase-4: A key player in chronic liver disease. World J Gastroenterol. 2013;19(15):2298. doi: https://doi.org/10.3748/wjg.v19.i15.2298</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Исмаилова Г.А. Влияние ингибиторов дипептидилпептидазы-4 на показатели липидного обмена у пациентов с сахарным диабетом 2-го типа в сочетании с метаболическим синдромом // Кардиология в Беларуси. — 2016. — Т. 1. — №44. — С. 138-147. [Ismailova G.A. Vliyanie ingibitorov dipeptidilpeptidazy-4 na pokazateli lipidnogo obmena u patsientov s sakharnym diabetom 2-go tipa v sochetanii s metabolicheskim sindromom. Kardiologiya v Belarusi. 2016;1(44):138-147. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Исмаилова Г.А. Влияние ингибиторов дипептидилпептидазы-4 на показатели липидного обмена у пациентов с сахарным диабетом 2-го типа в сочетании с метаболическим синдромом // Кардиология в Беларуси. — 2016. — Т. 1. — №44. — С. 138-147. [Ismailova G.A. Vliyanie ingibitorov dipeptidilpeptidazy-4 na pokazateli lipidnogo obmena u patsientov s sakharnym diabetom 2-go tipa v sochetanii s metabolicheskim sindromom. Kardiologiya v Belarusi. 2016;1(44):138-147. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Kusunoki M, Natsume Y, Miyata T, et al. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor. Drug Research. 2018;68(12):704-709. doi: https://doi.org/10.1055/a-0585-0145</mixed-citation><mixed-citation xml:lang="en">Kusunoki M, Natsume Y, Miyata T, et al. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor. Drug Research. 2018;68(12):704-709. doi: https://doi.org/10.1055/a-0585-0145</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Hasan AA, Hocher B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. Journal of Molecular Endocrinology. 2017;59(1):R1–R10. doi: https://doi.org/10.1530/jme-17-0005</mixed-citation><mixed-citation xml:lang="en">Hasan AA, Hocher B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. Journal of Molecular Endocrinology. 2017;59(1):R1–R10. doi: https://doi.org/10.1530/jme-17-0005</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Skov J. Effects of GLP-1 in the Kidney. Reviews in Endocrine and Metabolic Disorders. 2014;15(3):197-207. doi: https://doi.org/10.1007/s11154-014-9287-7</mixed-citation><mixed-citation xml:lang="en">Skov J. Effects of GLP-1 in the Kidney. Reviews in Endocrine and Metabolic Disorders. 2014;15(3):197-207. doi: https://doi.org/10.1007/s11154-014-9287-7</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvascular Research. 2012;84(3):395-398. doi: https://doi.org/10.1016/j.mvr.2012.06.008</mixed-citation><mixed-citation xml:lang="en">Ishibashi Y, Matsui T, Ojima A, et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvascular Research. 2012;84(3):395-398. doi: https://doi.org/10.1016/j.mvr.2012.06.008</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Sharkovska Y, Reichetzeder C, Alter M, et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J. Hypertens. 2014;32(11):2211-2223. doi: https://doi.org/10.1097/hjh.0000000000000328</mixed-citation><mixed-citation xml:lang="en">Sharkovska Y, Reichetzeder C, Alter M, et al. Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J. Hypertens. 2014;32(11):2211-2223. doi: https://doi.org/10.1097/hjh.0000000000000328</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA. 2019;321(1):69. doi: https://doi.org/10.1001/jama.2018.18269</mixed-citation><mixed-citation xml:lang="en">Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA. 2019;321(1):69. doi: https://doi.org/10.1001/jama.2018.18269</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Kabel AM, Omar MS, Alhadhrami A, et al. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1. Physiology &amp; Behavior. 2018;188:108-118. doi: https://doi.org/10.1016/j.physbeh.2018.01.028</mixed-citation><mixed-citation xml:lang="en">Kabel AM, Omar MS, Alhadhrami A, et al. Linagliptin potentiates the effect of l-dopa on the behavioural, biochemical and immunohistochemical changes in experimentally-induced Parkinsonism: Role of toll-like receptor 4, TGF-β1, NF-κB and glucagon-like peptide 1. Physiology &amp; Behavior. 2018;188:108-118. doi: https://doi.org/10.1016/j.physbeh.2018.01.028</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: https://doi.org/10.1056/NEJMoa1603827</mixed-citation><mixed-citation xml:lang="en">Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-322. doi: https://doi.org/10.1056/NEJMoa1603827</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Tonneijck L, Muskiet MHA, Smits MM, et al. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018;20(5):1235-1245. doi: https://doi.org/10.1111/dom.13223</mixed-citation><mixed-citation xml:lang="en">Tonneijck L, Muskiet MHA, Smits MM, et al. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018;20(5):1235-1245. doi: https://doi.org/10.1111/dom.13223</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Muskiet MH, Tonneijck L, Smits MM, et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab. 2016;18(2):178-185. doi: https://doi.org/10.1111/dom.12601</mixed-citation><mixed-citation xml:lang="en">Muskiet MH, Tonneijck L, Smits MM, et al. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men. Diabetes Obes Metab. 2016;18(2):178-185. doi: https://doi.org/10.1111/dom.12601</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Tonneijck L, Smits MM, Muskiet MHA, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016;59(7):1412-1421. doi: https://doi.org/10.1007/s00125-016-3938-z</mixed-citation><mixed-citation xml:lang="en">Tonneijck L, Smits MM, Muskiet MHA, et al. Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia. 2016;59(7):1412-1421. doi: https://doi.org/10.1007/s00125-016-3938-z</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Tonneijck L, Smits MM, Muskiet MH, et al. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2016;39(11):2042-2050. doi: https://doi.org/10.2337/dc16-1371</mixed-citation><mixed-citation xml:lang="en">Tonneijck L, Smits MM, Muskiet MH, et al. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2016;39(11):2042-2050. doi: https://doi.org/10.2337/dc16-1371</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Tonneijck L, Muskiet MHA, Smits MM, et al. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Diabetes Obes Metab. 2017;19(12):1669-1680. doi: https://doi.org/10.1111/dom.12985</mixed-citation><mixed-citation xml:lang="en">Tonneijck L, Muskiet MHA, Smits MM, et al. Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial. Diabetes Obes Metab. 2017;19(12):1669-1680. doi: https://doi.org/10.1111/dom.12985</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007;18(2):430-439. doi: https://doi.org/10.1681/ASN.2006040415</mixed-citation><mixed-citation xml:lang="en">Hagos Y, Stein D, Ugele B, et al. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol. 2007;18(2):430-439. doi: https://doi.org/10.1681/ASN.2006040415</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X, Huang Q, Feng J, et al. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway. J Int Med Res. 2021;49(2):030006052199298. doi: https://doi.org/10.1177/0300060521992981</mixed-citation><mixed-citation xml:lang="en">Chen X, Huang Q, Feng J, et al. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway. J Int Med Res. 2021;49(2):030006052199298. doi: https://doi.org/10.1177/0300060521992981</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Liu X, Huang J, Li J, et al. Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kB Levels in Type 2 Diabetes. J Coll Physicians Surg Pak. 2019;29(3):218-221. doi: https://doi.org/10.29271/jcpsp.2019.03.218</mixed-citation><mixed-citation xml:lang="en">Liu X, Huang J, Li J, et al. Effects of Liraglutide Combined with Insulin on Oxidative Stress and Serum MCP-1 and NF-kB Levels in Type 2 Diabetes. J Coll Physicians Surg Pak. 2019;29(3):218-221. doi: https://doi.org/10.29271/jcpsp.2019.03.218</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Dai Y, Dai D, Wang X, et al. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther. 2014;28(5):425-432. doi: https://doi.org/10.1007/s10557-014-6539-4</mixed-citation><mixed-citation xml:lang="en">Dai Y, Dai D, Wang X, et al. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther. 2014;28(5):425-432. doi: https://doi.org/10.1007/s10557-014-6539-4</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Fralick M, Chen SK, Patorno E, Kim SC. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2020;172(3):186-194. doi: https://doi.org/10.7326/M19-2610</mixed-citation><mixed-citation xml:lang="en">Fralick M, Chen SK, Patorno E, Kim SC. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study. Ann Intern Med. 2020;172(3):186-194. doi: https://doi.org/10.7326/M19-2610</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Yanardag R, Ozsoy-Sacan O, Orak H, Ozgey Y. Protective effects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes. Drug Chem Toxicol. 2005;28(4):483-497. doi: https://doi.org/10.1080/01480540500262961</mixed-citation><mixed-citation xml:lang="en">Yanardag R, Ozsoy-Sacan O, Orak H, Ozgey Y. Protective effects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes. Drug Chem Toxicol. 2005;28(4):483-497. doi: https://doi.org/10.1080/01480540500262961</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Hussain A, Latiwesh OB, Ali F, et al. Effects of Body Mass Index, Glycemic Control, and Hypoglycemic Drugs on Serum Uric Acid Levels in Type 2 Diabetic Patients. Cureus. 2018;10(8):e3158. doi: https://doi.org/10.7759/cureus.3158</mixed-citation><mixed-citation xml:lang="en">Hussain A, Latiwesh OB, Ali F, et al. Effects of Body Mass Index, Glycemic Control, and Hypoglycemic Drugs on Serum Uric Acid Levels in Type 2 Diabetic Patients. Cureus. 2018;10(8):e3158. doi: https://doi.org/10.7759/cureus.3158</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. Front Endocrinol (Lausanne). 2019;10:348. doi: https://doi.org/10.3389/fendo.2019.00348</mixed-citation><mixed-citation xml:lang="en">Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-Year Non-randomized Clinical Trial. Front Endocrinol (Lausanne). 2019;10:348. doi: https://doi.org/10.3389/fendo.2019.00348</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
